PlexBio
PlexBio is dedicated to advancing cancer research through the identification of meaningful genetic insights enabled by multiplexing technology. The company develops reliable multiplex testing solutions, instruments, and automated platforms that streamline lab workflows and deliver accurate results. With innovative core detection technology, the Precision Image Code MicroDisc, PlexBio enables the simultaneous detection of dozens to hundreds of biomarkers from a single specimen, focusing on cancer-related applications and offering assay solutions covering hundreds of genetic mutation sites. The company adheres to international standards, including CE-IVDR, TFDA GMP/QMS, and ISO13485, ensuring high product quality and safety. PlexBio aims to provide more accurate, convenient, and cost-competitive products, and is committed to revolutionizing and enhancing the diagnostic industry.
Industries
Nr. of Employees
medium (51-250)
PlexBio
6F-1, No. 351, Yangguang St., Neihu District, Taipei City 11491
Patents
Image differentiated multiplex assays for multiplex detection of DNA mutations
US-10894975-B2
View Details
Image differentiated multiplex assays for multiplex detection of DNA mutations
US-10894975-B2
View DetailsProducts
Image‑coded microdisc multiplexing platform
Integrated platform combining image‑decoded microdiscs and instrument readout to perform multiplex detection of many biomarkers from a single specimen for molecular diagnostics.
Automated sample preparation system
Instrument for automated nucleic acid extraction and sample processing designed to integrate with downstream multiplex assays and improve laboratory throughput.
Multiplex oncology and mutation reagent panels (blood and FFPE)
Reagent panels for detection of cancer-associated DNA and RNA mutations from blood (liquid biopsy) and FFPE samples, covering common oncogenic targets and mutation sites.
Infectious disease molecular assay kits (PCR‑based)
PCR-based molecular diagnostic kits for infectious diseases and respiratory pathogen panels, including SARS‑CoV‑2 and multi‑pathogen respiratory detection.
Calibration, buffers and consumables
Calibration kits, assay wash buffers, conjugation/coupling buffers, and other consumables required for multiplex assay setup, maintenance and quality control.
Instrument maintenance and service kits
Service and maintenance kits for diagnostic instruments to support uptime and routine servicing.
Image‑coded microdisc multiplexing platform
Integrated platform combining image‑decoded microdiscs and instrument readout to perform multiplex detection of many biomarkers from a single specimen for molecular diagnostics.
Automated sample preparation system
Instrument for automated nucleic acid extraction and sample processing designed to integrate with downstream multiplex assays and improve laboratory throughput.
Multiplex oncology and mutation reagent panels (blood and FFPE)
Reagent panels for detection of cancer-associated DNA and RNA mutations from blood (liquid biopsy) and FFPE samples, covering common oncogenic targets and mutation sites.
Infectious disease molecular assay kits (PCR‑based)
PCR-based molecular diagnostic kits for infectious diseases and respiratory pathogen panels, including SARS‑CoV‑2 and multi‑pathogen respiratory detection.
Calibration, buffers and consumables
Calibration kits, assay wash buffers, conjugation/coupling buffers, and other consumables required for multiplex assay setup, maintenance and quality control.
Instrument maintenance and service kits
Service and maintenance kits for diagnostic instruments to support uptime and routine servicing.
Services
End-to-end manufacturing and production services for diagnostic reagents and kits offered on a contract basis.
Development of bespoke molecular and immunology assays, including custom infectious-disease assay development and assay optimization for specific targets.
Technology licensing, co-development, and distribution partnership services to commercialize diagnostic platforms and assays.
End-to-end manufacturing and production services for diagnostic reagents and kits offered on a contract basis.
Development of bespoke molecular and immunology assays, including custom infectious-disease assay development and assay optimization for specific targets.
Technology licensing, co-development, and distribution partnership services to commercialize diagnostic platforms and assays.
Expertise Areas
- Multiplex molecular diagnostics
- Assay development for oncology and infectious disease
- Liquid biopsy and non‑invasive genomic profiling
- High‑throughput laboratory automation
Key Technologies
- Image‑differentiated microdisc multiplexing
- Fluorescence‑based detection
- Automated nucleic acid extraction
- Liquid biopsy genomic profiling
News & Updates
Partnership to introduce TRIO 240 to Taiwan market.
FDA certification received for the IntelliPrep TRIO System, enabling expansion into Korea.
Advancement of molecular diagnostic tools for SARS-CoV-2 variants.
Participation in Medlab Dubai to showcase lung cancer detection technology.
Participation in MEDICA to showcase molecular diagnostics.
Demonstration of multiplex diagnostics platform at Bio Boston 2023.
Partnership to introduce TRIO 240 to Taiwan market.
FDA certification received for the IntelliPrep TRIO System, enabling expansion into Korea.
Advancement of molecular diagnostic tools for SARS-CoV-2 variants.
Participation in Medlab Dubai to showcase lung cancer detection technology.
Participation in MEDICA to showcase molecular diagnostics.
Demonstration of multiplex diagnostics platform at Bio Boston 2023.